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Abstract Australia’s gene technology regulation
will be used to illustrate some key challenges
researchers should consider in the interface
between research and regulation. These challenges
result from the variety of legal obligations as well as
from the different viewpoints, motivations and
assumptions of researchers and regulators. Austra-
lia’s gene technology regulation is based on a
framework comprising both Commonwealth and
corresponding State and Territory legislation
designed to manage risks posed by genetically
modified organisms (GMOs). While the Gene Tech-
nology Regulator is an essential decision maker,
researchers may also need to interact with other
regulators when developing products for various
uses, such as those tasked with food safety, agri-
cultural and veterinary chemicals, therapeutics and
biosecurity. Each one of those regulators must sat-
isfy their relevant legislation and may, therefore,
require different information from the researcher.
The legislation under which each regulator is
required to operate is often prescriptive with regard
to the processes that must be followed and the
considerations that must be taken into account.
Amendments to the legislation are possible but may
be slow compared with the fast-paced and adaptive
nature of scientific research. Other challenges may
include: the desire of researchers to protect intel-
lectual property versus the public expectation of
transparency from regulators; or the notion in
researchers that genetically modified organisms are
simply organisms versus the regulator’s legislation
and risk oriented view. Challenges arising from dif-
ferences in focus and expectations can be overcome
by improving dialogue and engagement between
regulators and researchers. This will also lead to a
more robust regulatory system.
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1 Introduction
Most countries have regulatory systems based on
legislation for processes or products over which the
government wants to exercise control. The conduct
of scientific research can be overseen by a number of
different regulators with different objectives and
remits. This is particularly the case for research and
products involving new technologies, such as work
with gene technology, where society has expressed
concern and demanded assurances that the products
are safe. This makes dealing with regulation one of
the skills needed to work in biotechnology research.
The interface between researchers and those reg-
ulating their work can pose some challenges because
of the differing perspectives of those involved.
Researchers may see regulation as an unnecessary
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impost on their research, and perceive bureaucrats as
demanding more paperwork which gets in the way
of their ‘real’ work. The regulators may see their role
differently––that they are protecting the researcher
and the wider community from risks. As a result of
the contentious nature of gene technology, a regu-
lator can provide assurances to the community that
there is appropriate oversight of the work which can
in turn assist the researcher by supplying a ‘social
licence’ to operate (Lacey and Lamont 2013) for the
researcher.
This paper will explore some of the key consider-
ations that researchers should bear in mind when
approaching the challenges at the interface between
research and regulation, using Australia’s gene
technology regulatory system as an example.
2 Australia’s gene technology regulatory scheme
Work with gene technology in Australia is regulated
under the Gene Technology Act 2000 (the GTAct) and
the Gene Technology Regulations 2001 and a suite of
corresponding State and Territory legislation. The GT
Act regulates ‘dealings’ with genetically modified
organisms (GMOs), from initial experimental work in
the laboratory through to commercial release, to
protect human health and the environment. Infor-
mation gained at each step is used as the basis for a
science-based risk assessment, with management
conditions commensurate with the assessed risk. The
Australian scheme is broadly similar to regulatory
systems in many other countries. It accords with the
principle for biotechnology assessment established in
the early 1990s by the Organisation of Economic and
Cultural Development (OECD) (OECD 1992, 1993),
including the ‘blue book’ concept of a ‘step by step’
process proceeding from confinement to open to the
environment using the knowledge gained from each
step to develop familiarity (OECD 1986).
The GT Act establishes an independent statutory
office holder, the Gene Technology Regulator (the
Regulator), to administer the regulatory scheme. The
Regulator has extensive powers to monitor and
enforce the legislation and is supported in his role by
the Office of the Gene Technology Regulator (OGTR).
The Regulator makes decisions under the GT Act, but
changes to legislation and regulations must be made
by government.
The gene technology legislation was developed
with extensive community consultation. As a result of
the consultation, a number of key principles were
established including that:
• regulation operates as a part of an integrated
legislative framework with other Australian
agencies;
• the regulatory process is transparent and consul-
tative; and
• independent, science based assessments are used.
These are good principles and they underpin a
regulatory scheme that has been demonstrably
effective. However, they can create certain challenges
that researchers may face when interacting with the
gene technology regulatory scheme.
2.1 Which regulatory system applies?
As in many countries where new legislation has been
developed, Australia’s gene technology legislation
attempts to ‘fill a gap’ between existing pieces of
legislation. Importantly, the suite of regulation is
designed to avoid duplication and integrate the
activities of regulatory authorities with complemen-
tary responsibilities and expertise.
For some research activities approvals from dif-
ferent regulators may be needed. This arises from the
different regulators having different objectives and
different protection goals. For example, a GM plant
imported from overseas may require authorisation,
both under the GT Act to contain the GMO and the
Quarantine Act 1908, because the plant might carry
pests and diseases.
In the case of GM crops that are insect resistant or
herbicide tolerant, growing these crops in Australia
would require approval from the Regulator. They
would also require approval from the Australian
Pesticides and Veterinary Medicines Authority (AP-
VMA), which is responsible for regulating all
agricultural chemicals, to register the insecticide
product produced in the GM plant and/or approve
application of the herbicide to which the GM plants
are tolerant. A similar system exists in the European
union (EU) (Ehlers 2011).
The requirement for multiple regulatory approvals
means researchers may need to negotiate several sets
of regulations if they wish to commercialise a GMO. A
researcher/developer therefore needs to understand
what requires authorisation, who can provide the
authorisation and what they need to do to obtain the
authorisation. To help assist researchers, the regula-
tory agencies in Australia work together to avoid
duplication and ensure that thorough coordinated
assessments of parallel applications are undertaken
and, wherever possible, that the timing of decisions
by the agencies coincides. There are also reciprocal
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requirements for the various regulators to seek and
provide advice to each other to facilitate co-ordina-
tion of regulation.
The integrated legislative framework may also
mean that a researcher has to determine which reg-
ulatory agency has oversight of their work. This was
illustrated by researchers working with non-GM
Wolbachia-inoculated Aedes aegypti mosquitoes,
who were unsure which regulator should authorise
their field trial (De Barro et al. 2011). Such a situation
requires the researcher to have a clear understanding
of the regulatory schemes in place and for regulators
to communicate clearly with researchers about their
role.
2.2 National and state regulation
In many countries or jurisdictions, regulation may be
administered at a local rather than a national level.
This may be due to overlap in areas of responsibility
with state and federal laws or, in the case of Europe
for example, at the country rather than the EU level.
Australia, like many countries, has state govern-
ments as well as a federal (Commonwealth)
government, and there is a division of responsibilities
between federal and state governments. To ensure
complete regulatory coverage for gene technology,
the scheme was set up with a federal GT Act and an
agreement (Intergovernmental Gene Technology
Agreement 2001) that the States and Territories
would pass corresponding legislation. This ‘national
scheme’ was considered to be better than each State
and Territory having their own scheme (Ludlow
2004). It means that all organisations in Australia in
all jurisdictions are regulated in the same way and all
the corresponding gene technology legislation is
administered by the Regulator.
However, from a researcher’s perspective this can
create some complexities. A researcher needs to
understand whether they are regulated under State
or federal legislation depending on their organisa-
tion’s legal status. This is particularly important
following any changes to the federal law as some
States have to pass their own updated legislation, and
this may lead to a period of mismatch (The Allen
Consulting Group 2011).
Researchers may also have to navigate regulation
that is enacted for different reasons. For example in
Australia, the GTAct is focussed on protecting human
health and the environment. However, within the
national scheme, States and Territories can introduce
state-specific legislation to address trade and mar-
keting concerns [Gene Technology (Recognition of
Designated Areas) Policy Principle 2003]. In some
States, this means that researchers need to apply for
additional approvals to do research or conduct trials.
It has been suggested that this has created an
inconsistent and lengthy path to market for GMOs
(Gibbs et al. 2013) and may be inhibiting research
(Tasmanian Department of Primary Industries, Parks,
Water and Environment 2013).
3 Gene technology regulated by legislation
In most jurisdictions work with gene technology is
regulated by legislation, which provides a set of rules.
Laws impose requirements and prohibitions and
penalties for non-compliance, so the legislation must
provide clear boundaries to provide certainty for
researchers. The administration of legislation by a
regulator must, in turn, be uniform, consistent and
impartial. The apparent rigidity of legislation can be
challenging when regulating science which is, by
nature, changing and fast-paced and involves inno-
vative approaches.
Laws are made and revised by governments, and
administered by regulators. The laws themselves
often contain prescriptive definitions, requirements
and timeframes. It is possible for researchers to
influence the development of legislation at the
drafting or amending stage, where risks may have
changed due to new information or other factors and
indeed researchers are encouraged to engage in this
process. However, once legislation is enacted the
rules are set and must be implemented by the Reg-
ulator. This means that a researcher needs to plan
ahead and consider regulation, for example to avoid
potential issues with statutory assessment times
impacting on their ability to plant a GM field trial or
to make amendments to applications after they have
been submitted. Regulators can only accommodate
or consider requests from researchers within the
framework of the legislation. In Australia, the GT Act
allows the Regulator to agree, after assessment of any
risks, to certain changes to authorisations and
requirements after the licences have been issued.
These provisions are used frequently by researchers
to vary their original proposal in light of changed
circumstances, with 75 % of field trial licences varied
at least once.
A challenge for both regulators and researchers
relates to anticipating the future when advancing
any changes to legislation. This point was raised in
De Barro et al. (2011) in conjunction with regulation
of Wolbachia-inoculated mosquitos which he cites as
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an example of how science is ‘‘leading to advances
that outstrip existing regulatory frameworks and
underscores the need for researchers to engage pro-
actively with regulators to inform them of the
implications their science has for existing policy,
legislation and regulation’’.
The ability of legislation to respond to, and even
anticipate, advances in technology is also clearly
illustrated by the debate around regulation of new
plant breeding technologies and how these fit into
current regulatory schemes internationally (FSANZ
2013; Heap 2013; Kuzma and Kokotovich 2011). Dif-
ferent countries have different triggers for regulation
of biotechnology products, usually effected by legal
definitions. Some jurisdictions (including the EU and
Australia) have a technology ‘process’ trigger where
organisms or food are subject to regulation as GM if
the techniques involved are defined as GM in legis-
lation. Other jurisdictions (including Canada and
New Zealand for organisms) have a ‘product’ trigger
such as novelty of the introduced trait. This has
implications for researchers operating internation-
ally as to whether certain activities are regulated. A
recent review of Australia’s gene technology legisla-
tion (The Allen Consulting Group 2011) also
recognised that the development of new technolo-
gies is moving faster than the regulations and is thus
testing their limits. The Australian government has
committed to looking at how this can be resolved (All
governments’ response 2013).
4 Science based risk assessment
As with most countries, the Australian system for
regulation of GMOs is underpinned by science-based
risk assessment. This requires scientific data to verify
a researcher’s assertions, preferably from publicly
available, peer-reviewed sources. However, the infor-
mation required for the purposes of risk assessment is
often not necessarily the most straightforward or
interesting for a researcher to provide. Unlike some
schemes, the Australian gene technology legislation
does not allow a consideration of benefits. This
means that much of the data that a researcher may
collect is not required for use in assessments by the
Regulator.
Moreover, inmany cases the data that regulators are
looking for is a negative result, for example showing
no change in the weediness of a GM plant compared
with the non-GM parent, whereas researchers are
usually looking for improvements. For the release of
some crop plants there can also be key pieces of
information missing from the literature about impor-
tant aspects of the crop biology, which may not be
important for production but essential for regulatory
risk assessment. For example, scientists developingGM
sugarcanebecameawareof thepaucity of information
on flowering and seed set in commercial sugarcane in
Australia (Bonnett et al. 2007). It can be challenging for
amolecular biologist who is interested in developing a
GMplant to be askedbasic ecologyquestions about the
unmodified parent plant.
The Regulator has tried to describe clearly the
information that is required for a risk assessment, both
in the risk assessment framework, which describes the
approach to conducting risk assessments as well as the
quality of evidence that is required (OGTR 2013b), and
in application forms. These documents are periodi-
cally revised, for example, the plant field trial
application formwas significantly enhanced in 2013 to
provide links to example answers to assist with com-
pleting the form by illustrating the kind of
information required for conducting risk analysis.1
The new application form also incorporates aspects of
the new weed risk assessment methodology used for
assessments of GMOs (Keese et al. 2013). This material
is intended to clarify what information is required for
a GM plant field trial to assist the researcher to collect
and provide the necessary data.
5 Transparency and consultation in regulation
Stakeholder confidence depends both on having
robust regulatory systems and effective stakeholder
communication. Transparency and predictability in
regulation is essential––the regulated community
and the public must understand what a regulator
does, why they do it, and the basis on which decisions
are made.
When the Australian regulatory scheme for gene
technology was established, governments sought to
recognise and acknowledge both the potential of
gene technology to contribute to society and com-
munity concerns over its development and
deployment. The extensive consultation conducted
during development of the regulatory scheme
reflected the emphasis placed on community input
and participation in the decision-making process. A
recent survey of public attitudes to gene technology
by the Australian government Department of Indus-
try confirmed that there is a strong view in the
1 http://www.ogtr.gov.au/internet/ogtr/publishing.nsf/Content/
dirform-new-htm.
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community that public consultation improves the
quality of regulation of gene technology (55 %
agreed, Ipsos-Eureka 2010).
Australia’s gene technology regulatory system
requires consultation with relevant government
agencies, technical experts and the public on appli-
cations for release of GMOs into the environment.
The applicant also has an opportunity to comment
on the risk assessment and risk management plan
prepared for their proposed field trial or commercial
release, to ensure that it is accurate and that the
licence conditions are practicable and likely to
achieve desired outcomes. However, the requirement
to make information publicly available may, in some
cases, generate challenges for researchers, with
unexpected or even unwanted, interest from the
media or community organisations.
Although the GT Act contains provisions to main-
tain confidentiality of commercial information, there
is a public interest test associated with this, which is
seen as particularly important for a commercial
release of a GMO. This has challenged researchers
who, for various reasons, may not want to reveal
certain details of their research. It also requires that
researchers are aware of which pieces of their
research actually need to be protected, and which are
already in the public domain. The GT Act also
requires that GM field trial site details are publicly
available thus ensuring transparency and avoiding
potential accusations that information is being hid-
den from the public. This has led to researcher
concerns about possible vandalism of sites as has
happened in some countries (Houllier 2012, and data
collected by Kuntz).2 Fortunately such incidents have
not been widespread in Australia, with only once
incident to date (OGTR 2013a).
While it is a particular strength of the regulatory
system, the requirement for transparency and open-
ness about the research being conducted can also
mean that researchers have to think about how to
present their work to the public. Scientists are often
accused of ‘group-think’ (as described in Whyte 1989)
and may not always appreciate that sections of the
community may not share their views about the
benefits of their research, may misunderstand their
motives, or may find the language they use confus-
ing. Media interest in GM research may also require
that researchers talk about their research with jour-
nalists, who may not have a technical understanding
of the work, or be sympathetic to its outcomes. It can
also create an unwelcome focus on a particular
organisation, with campaigns being directed at or-
ganisations (e.g. Greenpeace 2010, 2011). To engage
effectively in the public discourse, researchers will
have to embrace an increasingly diverse range of
mechanisms such as social media, video messaging
and public debate (which were used, for example, in
discussions of a GM wheat trial in the UK.3
6 Communication
One of the challenges that researchers sometimes
face when dealing with regulators is a lack of a
common understanding. Effective communication is
critical both for researchers to gain a clear under-
standing of the regulatory scheme and for regulators
to understand the challenges faced by the research-
ers. There are many mechanisms by which
researchers can communicate to enhance their
understanding of the regulatory framework and to
promote awareness of their concerns within it. These
mechanisms can range from researchers querying
aspects of a risk assessment through to applying to
serve on a technical advisory committee or advocat-
ing changes to legislation through a formal review
process. Although it must be recognised that
researchers are not always unbiased participants in
this process (Bartsch 2014).
The Australian gene technology legislation has
been independently reviewed twice, in 2006 and 2011
(Commonwealth of Australia 2006; The Allen Con-
sulting Group 2011) and the supporting regulations
are periodically reviewed. These reviews are
informed by stakeholder input, including researchers
within the regulated community, who provide
important perspectives as to how the legislation can
be improved. Such reviews provide critical opportu-
nities for researchers to influence the direction of the
legislation and to try to address challenges within the
regulatory scheme. Historically, these reviews of
regulations have used experience and new informa-
tion to reduce the regulatory oversight of particular
dealings, commensurate with the risk they pose.
Researchers can also influence the administrative
and risk assessment processes used to implement
regulations, for example, as occurred with sugges-
tions to adapt established methodology for weed risk
assessment to strengthen environmental risk assess-
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7 Conclusions
In order for both regulators and researchers to deli-
ver important societal goals, it is crucial that they
communicate to understand the landscape from
their different viewpoints. Science is the common
language and getting the science right is pivotal to
the credibility of both the researcher and regulator.
As scientific understanding continues to advance,
regulatory systems require active engagement from
regulators, researchers and the public in their
respective spheres of influence to maintain effective,
fit for purpose regulation that addresses, and is seen
to address, society’s needs in terms of enabling safe
access to new technology.
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